Edition:
United States

Epizyme Inc (EPZM.OQ)

EPZM.OQ on NASDAQ Stock Exchange Global Select Market

14.05USD
18 Aug 2017
Change (% chg)

$-0.05 (-0.35%)
Prev Close
$14.10
Open
$13.95
Day's High
$14.30
Day's Low
$13.85
Volume
106,250
Avg. Vol
146,105
52-wk High
$18.40
52-wk Low
$7.03

EPZM.OQ

Chart for EPZM.OQ

About

Epizyme, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of... (more)

Overall

Beta: 2.14
Market Cap(Mil.): $821.45
Shares Outstanding(Mil.): 58.47
Dividend: --
Yield (%): --

Financials

  EPZM.OQ Industry Sector
P/E (TTM): -- 78.89 32.56
EPS (TTM): -2.06 -- --
ROI: -51.70 2.83 14.89
ROE: -59.18 5.09 16.13

BRIEF-Epizyme reports Q2 loss of $0.48/shr

* Epizyme reports second quarter 2017 financial results and clinical and business progress

Aug 04 2017

BRIEF-US Oncology Research and Epizyme establish collaboration to identify non-hodgkin lymphoma patients with EZH2 mutations

* US Oncology Research and Epizyme establish collaboration to identify non-hodgkin lymphoma patients with EZH2 mutations

Aug 01 2017

BRIEF-Epizyme announces Tazemetostat to be evaluated in NCI-COG pediatric MATCH trial

* Epizyme announces Tazemetostat to be evaluated in NCI’s recently initiated NCI-COG pediatric MATCH trial Source text for Eikon: Further company coverage:

Jul 24 2017

BRIEF-Epizyme expands clinical collaboration with Genentech

* Epizyme expands clinical collaboration to study tazemetostat and tecentriq® combination in nsclc

Jun 26 2017

BRIEF-Epizyme announces tazemetostat granted orphan drug designation

* Epizyme announces tazemetostat granted orphan drug designation for the treatment of soft tissue sarcoma Source text for Eikon: Further company coverage:

Jun 21 2017

BRIEF-Epizyme reports positive interim data from Phase 2 trial for tazemetostat

* Epizyme reports positive interim data from Phase 2 trial for tazemetostat in relapsed or refractory follicular lymphoma and dlbcl patients

Jun 14 2017

BRIEF-Epizyme quarterly loss per share $0.56

* Quarterly loss per share $0.56 Source text: (http://bit.ly/2qgKGVs) Further company coverage:

May 08 2017

BRIEF-Epizyme Earns $10 million milestone payment from Glaxosmithkline

* Epizyme earns $10 million milestone payment from glaxosmithkline for initiation of GLP Toxicology studies with novel methyltransferase inhibitor

May 04 2017

BRIEF-Epizyme announces tazemetostat fast track designation for follicular lymphoma and plenary session on Phase 2 NHL data at ICML

* Epizyme announces tazemetostat fast track designation for follicular lymphoma and plenary session on Phase 2 NHL data at ICML

Apr 25 2017

BRIEF-Epizyme qtrly loss per share $0.60

* Epizyme reports 2016 financial results and provides 2017 pipeline goals

Mar 09 2017

Competitors

  Price Chg
Eisai Co., Ltd (4523.T) ¥5,612 -81.00
Novartis AG (NOVN.S) CHF79.80 -0.85
GlaxoSmithKline plc (GSK.L) 1,490.00 -16.00
Celgene Corporation (CELG.OQ) $127.65 +0.07

Earnings vs. Estimates